HIV/AIDS Drug Development
Indolyl aryl sulfone NNRTIs inhibit drug-resistant RT mutants via selective targeting
Published in AIDS Vaccine Week, January 9th, 2006
According to recent research from Italy, "Indolyl aryl sulfone (IAS) nonnucleoside inhibitors have been shown to potently inhibit the growth of wild-type and drug-resistant human immunodeficiency virus type 1 (HIV-1), but their exact mechanism of action has not been elucidated yet.
"Here, we describe the mechanism of inhibition of HIV-1 reverse transcriptase (RT) by selected IAS derivatives."
"Our results showed that, depending on the substitutions introduced in the IAS common pharmacophore, these compounds can be made...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Vaccine Week
Source: AIDS Vaccine Week (2006-01-09)
More Articles from AIDS Vaccine Week
- HIV/AIDS Vaccine
Adenoviruses encoding HIV Tat and SIV Gag enhanced cellular immunity to SIV Gag - HIV/AIDS Vaccine
Boost regimen induced HIV type 1-specific T cells - HIV/AIDS Vaccine
HIV-1 Gag dimerization-induced assembly involves multi-step pathway - Diagnostics
HIV-associated cardiomyopathy can be detected early and may be effectively treated - Disease Control
High morbidity continues to be associated with diarrheal diseases - Feline Immunodeficiency Virus Therapy
Neutralizing Abs inactivate rHuG-CSF in FIV-infected cats on long-term therapy - More from this issue of AIDS Vaccine Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
